Table 1.
Epidemiological characteristics of Japanese patients with adult T‐cell leukemia–lymphoma, grouped by sex (n = 922)
| Characteristic | Total | Male | Female | M / F ratio | P‐value |
|---|---|---|---|---|---|
| Evaluable patients, n | 922 | 487 | 435 | 1.12 | |
| Year of diagnosis, n (%) | |||||
| 2010 | 468 (50.8) | 253 (51.9) | 215 (49.4) | 1.05 | 0.440 |
| 2011 | 454 (49.2) | 234 (48.1) | 220 (50.6) | 0.95 | |
| Age, years | |||||
| Median (min, IQR, max) | 68 (34, 60–75, 100) | 68 (34, 60–75, 100) | 67 (34, 61–76, 94) | 0.730 | |
| Mean (SD) | 67.5 (10.8) | 67.4 (10.5) | 67.7 (11.2) | 0.720 | |
| Age category, years, n (%) | |||||
| <40 | 9 (1.0) | 4 (0.8) | 5 (1.2) | 0.67 | 0.080 |
| 40–49 | 42 (4.6) | 22 (4.5) | 20 (4.6) | 0.98 | |
| 50–59 | 152 (16.5) | 84 (17.3) | 68 (15.6) | 1.11 | |
| 60–69 | 307 (33.3) | 151 (31.0) | 156 (35.9) | 0.86 | |
| 70–79 | 282 (30.6) | 167 (34.3) | 115 (26.4) | 1.30 | |
| 80–89 | 122 (13.2) | 57 (11.7) | 65 (14.9) | 0.79 | |
| ≥90 | 8 (0.9) | 2 (0.4) | 6 (1.4) | 0.29 | |
| Geographical area of hospital, n (%) | |||||
| Hokkaido–Tohoku | 50 (5.4) | 28 (5.8) | 22 (5.1) | 1.14 | 0.790 |
| Kanto | 59 (6.4) | 28 (5.8) | 31 (7.1) | 0.82 | |
| Chubu–Hokuriku | 55 (6.0) | 28 (5.8) | 27 (6.2) | 0.94 | |
| Kinki | 88 (9.5) | 44 (9.0) | 44 (10.1) | 0.89 | |
| Chugoku–Shikoku | 48 (5.2) | 29 (5.9) | 19 (4.4) | 1.34 | |
| Kyushu–Okinawa | 622 (67.5) | 330 (67.7) | 292 (67.1) | 1.01 | |
| Geographical areas of birth, n (%) | |||||
| Missing | 316 | 157 | 159 | ||
| Hokkaido–Tohoku | 45 (7.4) | 25 (7.6) | 20 (7.2) | 1.06 | 0.130 |
| Kanto | 10 (1.7) | 2 (0.6) | 8 (2.9) | 0.21 | |
| Chubu–Hokuriku | 17 (2.8) | 13 (3.9) | 4 (1.4) | 2.79 | |
| Kinki | 22 (3.6) | 11 (3.3) | 11 (4.0) | 0.83 | |
| Chugoku–Shikoku | 35 (5.8) | 18 (5.5) | 17 (6.2) | 0.89 | |
| Kyushu–Okinawa | 477 (78.7) | 261 (79.1) | 216 (78.3) | 1.01 | |
| Medical history, n (%) | |||||
| Transfusion before 1986, yes | 15 (1.7) | 5 (1.0) | 10 (2.3) | 0.43 | 0.130 |
| Skin diseases, yes | 43 (4.8) | 23 (4.7) | 20 (4.6) | 1.02 | 0.920 |
| Infectious diseases, yes | 98 (10.9) | 57 (11.7) | 41 (9.4) | 1.24 | 0.260 |
| Malignancies, yes | 108 (12.0) | 63 (12.9) | 45 (10.3) | 1.25 | 0.220 |
| Autoimmune diseases, yes | 36 (4.0) | 8 (1.6) | 28 (6.4) | 0.25 | <0.001 |
| Subtype by central review, n (%) | |||||
| Acute | 456 (49.5) | 241 (49.5) | 215 (49.4) | 1.00 | 0.007 |
| Lymphoma | 237 (25.7) | 141 (28.9) | 96 (22.1) | 1.31 | |
| Chronic | 131 (14.2) | 53 (10.9) | 78 (17.9) | 0.61 | |
| Smoldering | 98 (10.6) | 52 (10.7) | 46 (10.6) | 1.01 | |
ATL, adult T‐cell leukemia–lymphoma; F, female; IQR, interquartile range; M, male; max, maximum; min, minimum.